New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 11, 2014
09:03 EDTINOInovio repsonds to third party article regarding immunotherapy study
Inovio announced that it wishes to clarify that a third party article published on June 10, was misrepresentative of facts and can only be taken as malicious. The company said the referenced article does not reflect the progress, status, and potential of Inovio's active immune therapy technology and products and is rife with false and misleading conjecture. Inovio has indicated that it expects to report mid-year the top-line results of its phase II clinical trial evaluating VGX-3100 for the treatment of cervical dysplasia. Inovio said it designed the double blind, placebo controlled phase II study to comprehensively measure efficacy, HPV viral clearance, immunogenicity, and safety. At this time the data remains blinded and the company aims to report this data by the end of July. Inovio adds, "We are hopeful that these results could lead to a novel therapeutic option for women to avoid the invasive current surgical procedure. There exists the prospect that our immunotherapy approach may eliminate the presence of HPV virus to minimize future recurrences."
News For INO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 21, 2015
05:33 EDTINOInovio, Roche initiate clinical trial for DNA immunotherapy to treat HCB
Inovio Pharmaceuticals (INO) announced that it has initiated a Phase I trial to evaluate Inovio's DNA immunotherapy in patients who are chronically infected with hepatitis B. In 2013, Roche (RHHBY) and Inovio entered into a partnership to co-develop and commercialize Inovio's hepatitis B immunotherapy. This trial initiation triggers a $3M milestone payment from Roche to Inovio. This phase I, randomized, open-label, active-controlled, dose escalation study will evaluate the safety, tolerability, and immunogenicity of Inovio's hepatitis B immunotherapy, INO-1800, alone or in combination with INO-9112, Inovio's IL-12-based immune activator. This international study will enroll patients in the United States and Asia Pacific region with a primary endpoint of safety and tolerability of the therapy. The secondary endpoints will evaluate the cellular and humoral immune response to INO-1800 and investigate the therapy's effect on several viral and antiviral parameters. All trial subjects are also medicated with standard-of-care antiviral therapies.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use